David Dalrymple

David has over 15 years commercial experience in early-stage drug discovery, having started his career as a Business Development Manager at SB Drug Discovery in 2010. David became a Company Director of SB Drug Discovery and was responsible for driving all commercial activities, supporting its elevation to one of the industry’s largest ion channel focused CROs. Following acquisition of SB Drug Discovery by Sygnature in 2022, David was appointed Vice President, Discovery Services, where he oversees commercial activities to support Sygnature’s discipline-focused, standalone discovery capabilities.  

David holds a BSc Hons in Neuroscience and PhD in Molecular Virology from the University of Glasgow.